Tekijänoikeuden erikoiskirjasto

Compulsory Licences in a Regional Context : An Appraisal of the TRIPS Amendment’s Special Regional Treatment
Muistilista on tyhjä
Vis
Hylly
  • SA-GRUR International
Henkilönnimi
  • Adekola, Tolulope Anthony, kirjoittaja.
Nimeke- ja vastuullisuusmerkintö
  • Compulsory Licences in a Regional Context : An Appraisal of the TRIPS Amendment’s Special Regional Treatment
Julkaistu
  • Verlag C.H. Beck, München : 2022.
Ulkoasutiedot
  • s. 822–830
Sarjamerkintö ei-lisäkirjausmuodossa
  • GRUR International, ISSN 2632-8623 ; 71(9)
Huomautus sisällöstä, tiivistelmä tms.
  • Against the backdrop of the regional mechanism carved out under Art. 31bis(3) of the TRIPS Agreement for issuing compulsory licences, the paper critically appraises the mechanism’s viability or otherwise in addressing the challenge of access to essential medicines in a regional context. The paper finds that the mechanism remains severely restricted. First, it does not exempt an importing country within the regional alliance from issuing a separate compulsory licence where a patent is in force on the pharmaceutical product in question. Second, the logic of the mechanism is counterintuitive in that it is prohibited from being used as an instrument to pursue industrial policy objectives, and in a broad sense, a public-health-related industrial agenda. Using the East African Community (EAC) as a case study, the paper practically reveals how the identified distortions inhibit the use of compulsory licences within a regional coalition. The paper also examines how the potency of the TRIPS transition period, which excludes 80% of EAC member states from granting pharmaceuticals patents until 2034, is being whittled down by the African Regional Intellectual Property Organization’s (ARIPO) obligations and unclear domestic legislation. The paper recommends an overhaul of the TRIPS amendment’s regional mechanism for better effectiveness in driving pharmaceutical access.
Asiasana
Asiasana - Kontrolloimaton
Sarjalisäkirjaus - yhtenäistetty nimeke
  • GRUR International, 2632-8623 ; 71(9)
*000      ab a        ar
*00117181
*008      s2022||||gw |||||||||||||||||eng||            
*040  $aFI-CUTE$bfin$erda
*0410 $aeng
*1001 $aAdekola, Tolulope Anthony,$ekirjoittaja.
*24510$aCompulsory Licences in a Regional Context :$bAn Appraisal of the TRIPS Amendment’s Special Regional Treatment /$cTolulope Anthony Adekola.
*264 1$aMünchen :$bVerlag C.H. Beck,$c2022.
*300  $as. 822–830
*336  $ateksti$btxt$2rdacontent
*337  $akäytettävissä ilman laitetta$bn$2rdamedia
*338  $anide$bnc$2rdacarrier
*4901 $aGRUR International,$x2632-8623 ;$v71(9)
*520  $aAgainst the backdrop of the regional mechanism carved out under Art. 31bis(3) of the TRIPS Agreement for issuing compulsory licences, the paper critically appraises the mechanism’s viability or otherwise in addressing the challenge of access to essential medicines in a regional context. The paper finds that the mechanism remains severely restricted. First, it does not exempt an importing country within the regional alliance from issuing a separate compulsory licence where a patent is in force on the pharmaceutical product in question. Second, the logic of the mechanism is counterintuitive in that it is prohibited from being used as an instrument to pursue industrial policy objectives, and in a broad sense, a public-health-related industrial agenda. Using the East African Community (EAC) as a case study, the paper practically reveals how the identified distortions inhibit the use of compulsory licences within a regional coalition. The paper also examines how the potency of the TRIPS transition period, which excludes 80% of EAC member states from granting pharmaceuticals patents until 2034, is being whittled down by the African Regional Intellectual Property Organization’s (ARIPO) obligations and unclear domestic legislation. The paper recommends an overhaul of the TRIPS amendment’s regional mechanism for better effectiveness in driving pharmaceutical access.
*650 7$ateollisoikeus$2yso/fin$0http://www.yso.fi/onto/yso/p3067
*650 7$alisenssit$0http://www.yso.fi/onto/yso/p16495$2yso/fin
*650 7$apatentit$0http://www.yso.fi/onto/yso/p3069$2yso/fin
*650 7$alääketeollisuus$0http://www.yso.fi/onto/yso/p11187$2yso/fin
*650 7$alääkkeet$0http://www.yso.fi/onto/yso/p1077$2yso/fin
*653  $aTRIPS
*830 0$aGRUR International,$x2632-8623 ;$v71(9)
*852  $hSA-GRUR International
^
Tästä teoksesta ei ole arvioita.
Näpäytä kun haluat kirjoittaa ensimmäisen arvion.
Vis
Lähetä
Niteen tunnusTilaEräpäiväKuuluuSijaintiHylly
Ex1Saatavana (ei lainattavissa) KirjastoKirjasto SA-GRUR International